NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) is a clinical-stage biotechnology company focused on developing and commercializing novel, non-antibiotic anti-infective products designed to regulate the innate immune response. Leveraging its proprietary Aganocide® Technology, the company’s synthetic antimicrobial compounds target and neutralize pathogens without contributing to antibiotic resistance. NovaBay’s research and development efforts concentrate on ophthalmic, dermatological and wound care applications, aiming to address unmet needs in infection control and inflammation management.
The company’s primary commercial products include Avenova®, an eyelid and lash cleaning solution indicated for managing chronic blepharitis and meibomian gland dysfunction, and NeutroPhase®, a pure hypochlorous acid wound and skin cleanser used in acute and chronic wound irrigation. In addition, NovaBay has introduced i-Lid Cleanser®, a convenience-packaged foam for daily eyelid hygiene, and Nexagon®, a solution for pre-surgical prep and dermatological indications. These offerings have obtained FDA clearances and CE marks, supporting distribution across the United States, Canada, Europe and select international markets through strategic partnerships.
Founded in 2000 and headquartered in Emeryville, California, NovaBay underwent a name change from NeoPharm to NovaBay Pharmaceuticals in 2007 to reflect its broader focus on anti-infective immunology. Over the years, the company has built a pipeline of clinical-stage candidates—including investigational formulations for surgical prep and dermatological conditions—and has engaged in collaborations to expand its global footprint. Leadership is headed by President and CEO Joshua Disbrow, who brings extensive experience in life sciences commercialization, supported by a management team with backgrounds in clinical development, regulatory affairs and commercial operations.
Looking ahead, NovaBay continues to pursue regulatory approvals and licensing agreements aimed at deepening market penetration and funding ongoing clinical programs. By combining a novel mechanism of action with targeted delivery platforms, the company seeks to offer safe, effective alternatives to traditional antibiotics and antiseptics, addressing growing concerns over microbial resistance and providing clinicians with additional tools in infection management.
